Meeder Asset Management Inc. Increases Stock Holdings in CVS Health Corporation $CVS

Meeder Asset Management Inc. increased its position in CVS Health Corporation (NYSE:CVS) by 16.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 65,603 shares of the pharmacy operator’s stock after acquiring an additional 9,300 shares during the quarter. Meeder Asset Management Inc.’s holdings in CVS Health were worth $4,712,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Caitong International Asset Management Co. Ltd grew its position in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 281 shares in the last quarter. Swiss RE Ltd. purchased a new stake in shares of CVS Health in the fourth quarter worth $26,000. Sankala Group LLC bought a new stake in CVS Health during the fourth quarter valued at $28,000. Global Trust Asset Management LLC boosted its stake in CVS Health by 344.8% during the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock valued at $28,000 after buying an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. purchased a new position in CVS Health during the fourth quarter worth about $28,000. Institutional investors own 80.66% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Robert W. Baird raised their price target on CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a report on Wednesday, April 15th. Piper Sandler reissued an “overweight” rating and set a $113.00 price objective on shares of CVS Health in a report on Monday, June 1st. Argus upped their price objective on shares of CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday, May 14th. JPMorgan Chase & Co. lifted their target price on shares of CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Finally, Morgan Stanley boosted their price target on shares of CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a research note on Thursday, June 4th. Twenty-one analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.38.

Insider Buying and Selling

In other news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This represents a 87.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 3,441,551 shares of company stock valued at $323,703,977. Company insiders own 0.85% of the company’s stock.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS opened its first pharmacy-focused location in Houston and plans to roll out nearly 20 similar sites, signaling an effort to expand access to in-person pharmacy care and strengthen its retail footprint. CVS Pharmacy® celebrates opening of first pharmacy-focused location in Houston
• Positive Sentiment: Management reiterated a constructive stance on GLP-1 drugs and pharmacy economics, with CEO comments highlighting that insurers may eventually cover weight-loss drugs more broadly once prices fall, reinforcing CVS’s role in cost management and pharmacy benefit services. CVS Health CEO David Joyner warns private insurers won’t cover GLP-1s for weight loss until drug prices drop
• Positive Sentiment: CVS also floated cost-saving solutions and a settlement in Georgia that could reduce prescription costs for some patients, which may improve public perception and support demand for its pharmacy services. New CVS settlement could lower prescription costs for some Georgians
• Neutral Sentiment: Coverage around CVS education benefits and talent development highlights workforce stability, but it is unlikely to have an immediate impact on the stock. At CVS, education benefits strengthen talent pipelines
• Neutral Sentiment: Broader analyst and media discussion of CVS’s dividend and GLP-1 strategy has helped reinforce the investment case, but this appears more supportive than a near-term catalyst. How Investors May Respond To CVS (CVS) Dividend Move And GLP‑1 Strategy Across Its Health Platform

CVS Health Trading Down 0.1%

Shares of CVS stock opened at $107.36 on Monday. The business has a 50-day moving average price of $98.97 and a two-hundred day moving average price of $85.17. CVS Health Corporation has a 12-month low of $58.50 and a 12-month high of $108.97. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The firm has a market cap of $136.99 billion, a P/E ratio of 47.30, a price-to-earnings-growth ratio of 1.05 and a beta of 0.61.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities analysts anticipate that CVS Health Corporation will post 7.46 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be paid a dividend of $0.665 per share. The ex-dividend date of this dividend is Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.5%. CVS Health’s dividend payout ratio (DPR) is 117.18%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.